Wednesday, 14 October 2026European Markets

CRCAM ATL.VEND.CCI And STOREBRAND Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam atl.vend.cci (crav.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam atl.vend.cci (crav.pa) €80.60 4.61% 2.16%
storebrand (stb.ol) kr115.80 3.58% 15.55%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam atl.vend.cci (crav.pa)

4.61% forward dividend yield and 2.16% return on equity

caisse régionale de crédit agricole mutuel atlantique vendée provides banking products and services in france. it offers accounts and card services; real estate, personal, credit consolidation, student, work, housing transition, and vehicle loans; saving products; revolving credit; and life, home, car and 2-wheeler, health and welfare, leisure and daily, and borrower insurance products. the company also provides real estate investment, mobile payment, cash management, collection and payment, funding, trade and export financing, international solutions, financial engineering, and advisory services, as well as retirement saving solutions. it serves individuals, private banks, businesses, professionals, farmers, public community and social housing, and associations. the company was incorporated in 2001 and is headquartered in nantes, france. caisse régionale de crédit agricole mutuel atlantique vendée is a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam atl.vend.cci has a trailing twelve months eps of €13.62.

pe ratio

crcam atl.vend.cci has a trailing twelve months price to earnings ratio of 5.92. meaning, the purchaser of the share is investing €5.92 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.16%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam atl.vend.cci's stock is considered to be overbought (>=80).

more news about crcam atl.vend.cci.

2. storebrand (stb.ol)

3.58% forward dividend yield and 15.55% return on equity

storebrand asa provides insurance products and services in norway, the united states, japan, and sweden. it operates through four segments: savings, insurance, guaranteed pension, and other. the savings segment offers retirement savings, defined contribution pensions, asset management, and retail banking products. its insurance segment provides health insurance, property and casualty insurance, personal risk products, and employee-related and pension-related insurance products. the guaranteed pension segment offers long-term pension savings products, such as defined contribution pensions, paid-up policies, and individual capital and pension insurance products. its other segment provides life insurance products. it offers asset management, securities, banking, and investment services. the company serves private individuals, corporate and retail markets, companies, municipalities, and public sector. storebrand asa was founded in 1767 and is headquartered in lysaker, norway. storebrand asa is a subsidiary of the storebrand group.

earnings per share

as for profitability, storebrand has a trailing twelve months eps of kr10.18.

pe ratio

storebrand has a trailing twelve months price to earnings ratio of 11.38. meaning, the purchaser of the share is investing kr11.38 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.55%.

growth estimates quarters

the company's growth estimates for the ongoing quarter is 27.3% and a drop 2.2% for the next.

more news about storebrand.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com